| 產(chǎn)品名稱 |
DAL K29 |
| 商品貨號(hào) |
B164328 |
| Organism |
Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type |
hybridoma: B lymphocyte |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease |
Carcinoma |
| Applications |
The hybridoma cell line DAL K29 secretes a mouse monoclonal antibody (IgG1) reactive with human normal glomeruli, renal cell carcinoma and prostatic acini.
This antibody as well as DAL K20 (ATCC CRL-2288) and DAL 45 (ATCC CRL-2292) is useful for identifying kidney differentiation antigens and has been shown effective in radioimaging as well as tumor growth inhibition in xenograft models.
The line was produced by fusing SP2 myeloma cells with spleen cells from BALB/c mice that had been immunized with the Caki-1 clear cell kidney carcinoma cell line. |
| Storage Conditions |
liquid nitrogen vapor phase |
| Derivation |
The line was produced by fusing SP2 myeloma cells with spleen cells from BALB/c mice that had been immunized with the Caki-1 clear cell kidney carcinoma cell line. |
| Genes Expressed |
immunoglobulin; monoclonal antibody; against human normal tubules, renal cell carcinoma and the basal layer of fetal or neonatal epidermis |
| Cellular Products |
immunoglobulin; monoclonal antibody; against human normal tubules, renal cell carcinoma and the basal layer of fetal or neonatal epidermis |
| Comments |
The hybridoma cell line DAL K29 secretes a mouse monoclonal antibody (IgG1) reactive with human normal glomeruli, renal cell carcinoma and prostatic acini.
DAL K29 precipitates molecules with molecular weighs of 118,000 and 150,000 from extracts of surface-labeled Caki-1 (ATCC HTB-46) cells.
This antibody as well as DAL K20 (ATCC CRL-2288) and DAL 45 (ATCC CRL-2292) is useful for identifying kidney differentiation antigens and has been shown effective in radioimaging as well as tumor growth inhibition in xenograft models.
The line was produced by fusing SP2 myeloma cells with spleen cells from BALB/c mice that had been immunized with the Caki-1 clear cell kidney carcinoma cell line. |
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing |
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 x 105 viable cells/mL. Maintain cell density between 1 x 105 and 1 x 106 viable cells/mL.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
|
| Cryopreservation |
Complete growth medium described above supplemented with 5% (v/v) DMSO. Cell culture tested DMSO is available as ATCC Catalog No. 4-X. |
| Culture Conditions |
Temperature: 37°C
Atmosphere: Air, 95%; Carbon dioxide (CO2), 5% |
| Isotype |
IgG1 |
| Name of Depositor |
SJ Luner, T Ghose |
| References |
Luner SJ, et al. Monoclonal antibodies to kidney and tumor-associated surface antigens of human renal cell carcinoma. Cancer Res. 46: 5816-5820, 1986. PubMed: 3530441
Guha AK, et al. Tumor localization of monoclonal antibodies against human renal carcinoma in a xenograft model. Cancer Lett. 61: 35-43, 1991. PubMed: 1764696
|
